Shanghai, China – November 16, 2025 — MicroPort® CardioFlow (02160.HK) has reached a critical milestone in its international expansion, with over 1,000 commercial implantations of its VitaFlow® TAVI systems performed outside of China. Nearly 30% of these procedures took place in Europe, the achievement signals a critical breakthrough in the company’s globalization strategy and a transition into high-quality, large-scale international growth.
The company’s flagship second-generation system, VitaFlow Liberty®, is now available in 32 countries, with rapid uptake in Europe, Latin America, and Asia. As of October 2025, the system has been adopted by 800+ hospitals and supported more than 17,000 procedures worldwide.
This milestone reflects the success of MicroPort® CardioFlow’s dual-channel global strategy, combining direct operations with localized distributor networks, and backed by strong clinical evidence and continuous product innovation.
As part of a broader pipeline, MicroPort® CardioFlow is also advancing multiple next-generation heart valve and structural heart solutions across TAVI, TMVR, TTVR, and stroke prevention, reinforcing its position as a global player in structural heart innovation.
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation, HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic research and development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at: https://en.cardioflowmedtech.com/